Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Stephen Frederick Moss is active.

Publication


Featured researches published by Stephen Frederick Moss.


Archive | 2004

Biaryl compounds having activity at the 5ht5a receptor

Steven Mark Bromidge; David F. Corbett; Thomas Daniel Heightman; Stephen Frederick Moss


Archive | 2002

7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders

Mahmood Ahmed; Steven Mark GlaxoSmithKline SpA Bromidge; Ian Thomson GlaxoSmithKline Forbes; Andrew Derrick GlaxoSmithKline Gribble; Christopher Norbert GlaxoSmithKline Johnson; Francis David GlaxoSmithKline King; Andrew P. Lightfoot; Gregor James GlaxoSmithKline Macdonald; Stephen Frederick Moss; Mervyn GlaxoSmithKline Thompson; David R. Witty


Archive | 2003

Quinoline and aza-indole derivatives and their use as 5-ht6 ligands

Christopher Norbert GlaxoSmithKline Johnson; Gregor James GlaxoSmithKline Macdonald; Darren Jason Mitchell; Stephen Frederick Moss; Mervyn GlaxoSmithKline Thompson; David R. GlaxoSmithKline Witty


Archive | 2003

Benzenesulfonamide derivatives as antipsychotic agents

Steven Mark Bromidge; David Gwyn Cooper; Ian Thomson GlaxoSmithKline Forbes; Andrew Derrick GlaxoSmithKline Gribble; Christopher Norbert GlaxoSmithKline Johnson; Andrew P. Lightfoot; Stephen Frederick Moss; Andrew H. Payne; Shahzad Sharooq GlaxoSmithKline Rahman; David R. Witty


Archive | 2003

7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders

Steven Mark Bromidge; Christopher Norbert GlaxoSmithKline Johnson; Stephen Frederick Moss; Shahzad Sharooq GlaxoSmithKline Rahman; David R. Witty


Archive | 2003

QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS

Mahmood Ahmed; Christopher Norbert GlaxoSmithKline Johnson; Martin Jones; Gregor James GlaxoSmithKline Macdonald; Stephen Frederick Moss; Mervyn GlaxoSmithKline Thompson; Charles Edward Wade; David R. GlaxoSmithKline Witty


Archive | 2004

8- (1-piperazinyl)- quinoline derivatives and their use in the treatment of cns disorders

Christopher Norbert GlaxoSmithKline Johnson; Stephen Frederick Moss; Malcolm M. GlaxoSmithKline Tait; David R. GlaxoSmithKline Witty


Archive | 2004

Piperazinyl-quinoline derivatives useful for the treatment of cns disorders

Christopher Norbert GlaxoSmithKline Johnson; Stephen Frederick Moss; David R. GlaxoSmithKline Witty


Archive | 2006

4-amino-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, neurological and cardiovascular disorders

Mahmood Ahmed; Neil Derek Miller; Peter Henry Milner; Stephen Frederick Moss; Mervyn Thompson


Archive | 2007

5-amino-6-bromo-n-{ [1- (tetrahydr0-2h-pyran-4-ylmethyl) -4-piperidinyl] methyl}-3, 4 -dihydro-2h-chromene-8-carboxamide as 5-ht4 receptor agonist

Mahmood Ahmed; Neil Derek Miller; Stephen Frederick Moss; Gareth John Sanger

Collaboration


Dive into the Stephen Frederick Moss's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge